The importance and clinical relevance of surfaces in tissue culture

Article English OPEN
Hickman, GJ ; Boocock, DJ ; Pockley, AG ; Perry, CC (2016)

Cell and tissue culture has evolved from the use of simple glassware for the propagation of cells and tissues into a comprehensive platform for interrogating complex biological systems, directing cell fate and deriving products with clinical and therapeutic value. However, despite significant advances, current in vitro culture approaches remain limited in their capacity to model the clinical/biological complexities of disease, in part at least due to the deficiencies of existing culture materials. The challenge is therefore to identify innovative materials-based solutions that have greater control over cells in vitro, while better representing biological systems in vivo. Such platforms would be suitable for biomarker discovery and tissue engineering applications. This review examines the development of tissue culture materials, advances in our understanding of cell-surface interactions and the application of this knowledge towards the development of new approaches for better examining biological events.
  • References (71)
    71 references, page 1 of 8

    8. Astashkina, A.; Mann, B.; Grainger, D. W. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 2012, 134, 82- 106, DOI: 10.1016/j.pharmthera.2012.01.001.

    9. Gillet, J-P.; Varma, S.; Gottesman, M. M. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 2013, 105, 452-458, DOI: 10.1093/jnci/djt007.

    10. McMurray, R. J.; Gadegaard, N.; Tsimbouri, P. M.; Burgess, K. V.; McNamara, L. E.; Tare, R.; Murawski, K.; Kingham, E.; Oreffo, R. O.; Dalby, M. J. Nanoscale surfaces for the long-term maintenance of mesenchymal stem cell phenotype and multipotency. Nat. Mater. 2011, 10, 637-644, DOI: 10.1038/nmat3058.

    11. Hutchinson, L., Kirk, R. High drug attrition rates - where are we going wrong? Nat. Rev. Clin. Oncol. 2011, 8, 189-190, DOI: 10.1038/nrclinonc.2011.34.

    12. Begley, C. G.; Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 2012, 483, 531-533, DOI: 10.1038/483531a.

    13. Hünig, T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 2012, 12, 317-318, DOI: 10.1038/nri3192.

    14. Lee, S.; Tang, C.; Rao, M. S.; Weissman, I. L.; Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 2013, 19, 998-1004, DOI: 10.1038/nm.3267.

    15. Smoliga, J. M, Vang, O, Baur, J. A. Challenges of translating basic research into therapeutics: resveratrol as an example. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 158- 167, DOI: 10.1093/gerona/glr062.

    16. Mak, I. W.; Evaniew, N.; Ghert, M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 2014, 6, 114-118

    17. Flecknell, P. Replacement, reduction and refinement. ALTEX 2002, 19, 73-78

  • Related Research Results (2)
  • Metrics
    views in OpenAIRE
    views in local repository
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    Institutional Repository - IRUS-UK 0 36
Share - Bookmark